These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25682871)

  • 1. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
    Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
    Wei Q; Clarke L; Scheidenhelm DK; Qian B; Tong A; Sabha N; Karim Z; Bock NA; Reti R; Swoboda R; Purev E; Lavoie JF; Bajenaru ML; Shannon P; Herlyn D; Kaplan D; Henkelman RM; Gutmann DH; Guha A
    Cancer Res; 2006 Aug; 66(15):7429-37. PubMed ID: 16885338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
    Jiang Z; Pore N; Cerniglia GJ; Mick R; Georgescu MM; Bernhard EJ; Hahn SM; Gupta AK; Maity A
    Cancer Res; 2007 May; 67(9):4467-73. PubMed ID: 17483362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma.
    Chen H; Shen X; Guo C; Zhu H; Zhou L; Zhu Y; Wang H; Zheng Y; Huang L
    Cancer Biother Radiopharm; 2010 Dec; 25(6):713-21. PubMed ID: 21204766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
    Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
    Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
    Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
    Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.
    Li L; Dutra A; Pak E; Labrie JE; Gerstein RM; Pandolfi PP; Recht LD; Ross AH
    Neuro Oncol; 2009 Feb; 11(1):9-21. PubMed ID: 18812521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.